Cytodyn Inc (CYDY)

[BlackDoggie]

In a word - yes, it's that simple. Most institutional investors and hedge funds are limited, either by policy or statutorily, from investing in OTC markets directly. Therefore, uplisting would allow massive buy side pressure assuming that there is interest. Also, any open shorts would have to cover at uplisting since the ticker closes and a new one is issued, which would add more buy side pressure. Uplisting would very likely be a good thing for SP, even with all the warrants out there that might cash in at that point.

Good question on the criteria for patients in clinical trials vs. use on the market. That's above my pay grade. I'm sure Misiu could provide good information here if she's around, as well as any of our other friends with a medical background or extensive biotech experience...